Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 164

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

The Potential Role and Rationale for Treatment of Heart Failure with Sodium–Glucose Co-Transporter 2 Inhibitors

Open access
Butler, Javed, Hamo, Carine E., Filippatos, Gerasimos, Pocock, Stuart J., Bernstein, Richard A., Brueckmann, Martina, Cheung, Alfred K., George, Jyothis T., Green, Jennifer B., Januzzi, James L., Kaul, Sanjay, Lam, Carolyn S.P., Lip, Gregory Y.H., Marx, Nikolaus, McCullough, Peter A., Mehta, Cyrus R., Ponikowski, Piotr, Rosenstock, Julio, Sattar, Naveed, Salsali, Afshin, Scirica, Benjamin M., Shah, Sanjiv J., Tsutsui, Hiroyuki, Verma, Subodh, Wanner, Christoph, Woerle, Hans-Juergan, Zannad, Faiez, Anker, Stefan D.·2017·European Journal of Heart Failure

Abstract

Heart failure (HF) and type 2 diabetes mellitus (T2DM) are both growing public health concerns contributing to major medical and economic burdens to society. T2DM increases the risk of HF, frequently occurs concomitantly with HF, and worsens the prognosis of HF. Several anti-hyperglycaemic medications have been associated with a concern for worse HF outcomes. More recently, the results of the EMPA-REG OUTCOME trial showed that the sodium–glucose co-transporter 2 (SGLT2) inhibitor empagliflozin was associated with a pronounced and precocious 38% reduction in cardiovascular mortality in subjects with T2DM and established cardiovascular disease [Correction added on 8 September 2017, after first online publication: “32%” in the previous sentence was corrected to “38%”]. These benefits were more related to a reduction in incident HF events rather than to ischaemic vascular endpoints. Several mechanisms have been put forward to explain these benefits, which also raise the possibility of using these drugs as therapies not only in the prevention of HF, but also for the treatment of patients with established HF regardless of the presence or absence of diabetes. Several large trials are currently exploring this postulate.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ejhf.933

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 56

  1. World Health Organization, 2016, Global Report on Diabetes
  2. Ray, 2009, Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials, Lancet, 373, 1765, 10.1016/S0140-6736(09)60697-8 · DOI · Paper page
  3. Grundy, 1999, Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association, Circulation, 100, 1134, 10.1161/01.CIR.100.10.1134 · DOI · Paper page
  4. Fitchett, 2017, Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes, Eur J Heart Fail, 19, 43, 10.1002/ejhf.633 · DOI
  5. Lloyd-Jones, 2002, Lifetime risk for developing congestive heart failure: the Framingham Heart Study, Circulation, 106, 3068, 10.1161/01.CIR.0000039105.49749.6F · DOI · Paper page
  6. Swan, 1997, Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure, J Am Coll Cardiol, 30, 527, 10.1016/S0735-1097(97)00185-X · DOI · Paper page
  7. Owan, 2006, Trends in prevalence and outcome of heart failure with preserved ejection fraction, N Engl J Med, 355, 251, 10.1056/NEJMoa052256 · DOI · Paper page
  8. Zhou, 2009, Prevalence, incidence and risk factors of chronic heart failure in the type 2 diabetic population: systematic review, Curr Diabetes Rev, 5, 171, 10.2174/157339909788920938 · DOI
  9. Dinesh Shah, 2015, Type 2 diabetes and incidence of a wide range of cardiovascular diseases: a cohort study in 1.9 million people, Lancet, 385
  10. McMurray, 2014, Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored, Lancet Diabetes Endocrinol, 2, 843, 10.1016/S2213-8587(14)70031-2 · DOI · Paper page
  11. Home, 2009, Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial, Lancet, 373, 2125, 10.1016/S0140-6736(09)60953-3 · DOI · Paper page
  12. Lincoff, 2007, Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials, JAMA, 298, 1180, 10.1001/jama.298.10.1180 · DOI · Paper page
  13. McAlister, 2008, The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy, Eur J Heart Fail, 10, 703, 10.1016/j.ejheart.2008.05.013 · DOI
  14. Rosenstock, 2013, Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial, Diab Vasc Dis Res, 10, 289, 10.1177/1479164112475102 · DOI
  15. Dahlof, 2002, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol, Lancet, 359, 995, 10.1016/S0140-6736(02)08089-3 · DOI · Paper page
  16. Julius, 2004, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial, Lancet, 363, 2022, 10.1016/S0140-6736(04)16451-9 · DOI · Paper page
  17. Solomon, 2004, Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program, Circulation, 110, 2180, 10.1161/01.CIR.0000144474.65922.AA · DOI · Paper page
  18. Zile, 2010, Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial, Circulation, 121, 1393, 10.1161/CIRCULATIONAHA.109.909614 · DOI · Paper page
  19. Cleland, 2006, The perindopril in elderly people with chronic heart failure (PEP-CHF) study, Eur Heart J, 27, 2338, 10.1093/eurheartj/ehl250 · DOI · Paper page
  20. Fang, 2016, Heart failure with preserved ejection fraction: a kidney disorder?, Circulation, 134, 435, 10.1161/CIRCULATIONAHA.116.022249 · DOI
  21. Fitchett, 2017, Reduction in hospitalisation for heart failure with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: results from the EMPA-REG OUTCOME trial [abstract], Eur J Heart Fail, 19, 121
  22. Jorsal, 2017, Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial, Eur J Heart Fail, 19, 69, 10.1002/ejhf.657 · DOI · Paper page
  23. Heerspink, 2016, Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications, Circulation, 134, 752, 10.1161/CIRCULATIONAHA.116.021887 · DOI · Paper page
  24. Nauck, 2014, Update on developments with SGLT2 inhibitors in the management of type 2 diabetes, Drug Des Devel Ther, 8, 1335, 10.2147/DDDT.S50773 · DOI · Paper page
  25. Sattar, 2016, SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?, Diabetologia, 59, 1333, 10.1007/s00125-016-3956-x · DOI · Paper page
  26. Inzucchi, 2015, SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials, Diab Vasc Dis Res, 12, 90, 10.1177/1479164114559852 · DOI · Paper page
  27. Cherney, 2014, Renal hemodynamic effect of sodium–glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus, Circulation, 129, 587, 10.1161/CIRCULATIONAHA.113.005081 · DOI · Paper page
  28. Rajasekeran, 2016, Sodium–glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis, Kidney Int, 89, 524, 10.1016/j.kint.2015.12.038 · DOI
  29. Heise, 2016, Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes, Clin Ther, 38, 2265, 10.1016/j.clinthera.2016.09.001 · DOI
  30. Liu, 2014, Inhibiting mitochondrial Na+/Ca2+ exchange prevents sudden death in a Guinea pig model of heart failure, Circ Res, 115, 44, 10.1161/CIRCRESAHA.115.303062 · DOI · Paper page
  31. Layton, 2015, Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition, Am J Physiol Renal Physiol, 308, F1343, 10.1152/ajprenal.00007.2015 · DOI
  32. Inoue, 2012, Increased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failure, Am J Physiol Regul Integr Comp Physiol, 302, R166, 10.1152/ajpregu.00127.2011 · DOI
  33. Verbrugge, 2014, The kidney in congestive heart failure: ‘are natriuresis, sodium, and diuretics really the good, the bad and the ugly?’, Eur J Heart Fail, 16, 133, 10.1002/ejhf.35 · DOI · Paper page
  34. Verbrugge, 2015, SGLT-2 inhibitors: potential novel strategy to prevent congestive heart failure in diabetes?, Curr Cardiovasc Risk Rep, 9, 38, 10.1007/s12170-015-0467-0 · DOI
  35. Bautista, 2004, Angiotensin II-dependent increased expression of Na+-glucose cotransporter in hypertension, Am J Physiol Renal Physiol, 286, F127, 10.1152/ajprenal.00113.2003 · DOI
  36. Vasilakou, 2013, Sodium–glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis, Ann Intern Med, 159, 262, 10.7326/0003-4819-159-4-201308200-00007 · DOI · Paper page
  37. Riggs, 2015, The use of SGLT-2 inhibitors in type 2 diabetes and heart failure, Metab Syndr Relat Disord, 13, 292, 10.1089/met.2015.0038 · DOI
  38. Rosengren, 2017, Body weight in adolescence and long-term risk of early heart failure in adulthood among men in Sweden, Eur Heart J, 38, 1926
  39. Heerspink, 2011, The kidney in type 2 diabetes therapy, Rev Diabet Stud, 8, 392, 10.1900/RDS.2011.8.392 · DOI
  40. Hamano, 2008, Associations of renal vascular resistance with albuminuria and other macroangiopathy in type 2 diabetic patients, Diabetes Care, 31, 1853, 10.2337/dc08-0168 · DOI
  41. Lytvyn, 2015, Uric acid as a biomarker and a therapeutic target in diabetes, Can J Diabetes, 39, 239, 10.1016/j.jcjd.2014.10.013 · DOI
  42. Filippatos, 2011, Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data, Eur Heart J, 32, 712, 10.1093/eurheartj/ehq473 · DOI
  43. Lytvyn, 2015, Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus, Am J Physiol Renal Physiol, 308, F77, 10.1152/ajprenal.00555.2014 · DOI · Paper page
  44. Oelze, 2014, The sodium–glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity, PLoS One, 9, 10.1371/journal.pone.0112394 · DOI · Paper page
  45. Zinman, 2016, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N Engl J Med, 374, 1094
  46. Sano, 2016, Increased hematocrit during sodium–glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys, J Clin Med Res, 8, 844, 10.14740/jocmr2760w · DOI · Paper page
  47. Chang, 2016, Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury, PLoS One, 11
  48. Tahara, 2013, Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice, Eur J Pharmacol, 715, 246, 10.1016/j.ejphar.2013.05.014 · DOI · Paper page
  49. Shah, 2012, Increased arterial wave reflection magnitude: a novel form of stage B heart failure?, J Am Coll Cardiol, 60, 2178, 10.1016/j.jacc.2012.07.055 · doi:10.1016/j.jacc.2012.07.055
  50. Jones, 2012, Minireview: Glucagon in stress and energy homeostasis, Endocrinology, 153, 1049, 10.1210/en.2011-1979 · DOI
  51. Mery, 1990, Glucagon stimulates the cardiac Ca2+ current by activation of adenylyl cyclase and inhibition of phosphodiesterase, Nature, 345, 158, 10.1038/345158a0 · DOI
  52. Ferrannini, 2016, Shift to fatty substrate utilization in response to sodium–glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes, Diabetes, 65, 1190, 10.2337/db15-1356 · DOI · Paper page
  53. Lopaschuk, 2016, Empagliflozin's fuel hypothesis: not so soon, Cell Metab, 24, 200, 10.1016/j.cmet.2016.07.018 · DOI
  54. Verma, 2016, Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial?, Diabetes Care, 39, e212, 10.2337/dc16-1312 · DOI · Paper page
  55. Shi, 2017, Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?, Mol Cell Biochem, 10.1007/s11010-017-3018-9 · DOI
  56. Neal, 2013, Rationale, design, and baseline characteristics of the Canagliflozin cardiovascular assessment study (CANVAS)—a randomized placebo-controlled trial, Am Heart J, 166, 217, 10.1016/j.ahj.2013.05.007 · DOI · Paper page

Cited by

See all 164

Metadata

Authors
Butler, J., Hamo, C. E., Filippatos, G., Pocock, S. J., Bernstein, R. A., Brueckmann, M., Cheung, A. K., George, J. T., Green, J. B., Januzzi, J. L., Kaul, S., Lam, C. S. P., Lip, G. Y. H., Marx, N., McCullough, P. A., Mehta, C. R., Ponikowski, P., Rosenstock, J., Sattar, N., Salsali, A., Scirica, B. M., Shah, S. J., Tsutsui, H., Verma, S., Wanner, C., Woerle, H.-J., Zannad, F., & Anker, S. D.
Venue
European Journal of Heart Failure
Published
2017-08-24
Volume
19
Issue
11
Pages
1390-1400
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2746903407
Cited by
164
References
31
FWCI
1.68
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.